• Tomasz Szmuda, Przemyslaw M Waszak, Cezary Rydz, Janusz Springer, Lukasz Budynko, Anna Szydlo, Pawel Sloniewski, and Jarosław Dzierżanowski.
• Department of Neurosurgery, Medical University of Gdansk, Gdansk, Poland. Electronic address: tszmuda@gumed.edu.pl.
• Neurol Neurochir Pol. 2014 Jan 1; 48 (5): 328-36.

PurposeThe triple-H therapy is widely used for cerebral vasospasm (CV) prevention and treatment in patients after subarachnoid haemorrhage (SAH). However, this practice is based on low level evidence. Aim of this study was to evaluate errors in fluid administration, fluid balance monitoring and bedside charts completeness during a trial of triple-H therapy.Materials And MethodsAn audit of the SAH patient charts was performed. A total of 508 fluid measurements were performed in 41 patients (6 with delayed cerebral ischaemia; DCI) during 14 days of observation.ResultsUnderestimating for intravenous drugs was the most frequent error (80.6%; 112), resulting in a false positive fluid balance in 2.4% of estimations. In 38.6% of the negative fluid balance cases, the physicians did not order additional fluids for the next 24h. In spite of that, the fluid intake was significantly increased after DCI diagnosis. The mean and median intake values were 3.5 and 3.8l/24h respectively, although 40% of the fluid balances were negative. The positive to negative fluid balance ratio was decreasing in the course of the 14 day observation.ConclusionsThis study revealed inconsistencies in the fluid orders as well as mistakes in the fluid monitoring, which illustrates the difficulties of fluid therapy and reinforces the need for strong evidence-based guidelines for hypervolemic therapy in SAH.Copyright © 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

17 keywords...

hide…